Abzu, a member of Catalonia.health, and ADViRNA, a boutique U.S.-based CRO, are joining forces to develop novel siRNA therapeutics. This collaboration combines Abzu’s AI-driven siRNA design platform with ADViRNA’s wet-lab expertise from sequence design through in vivo validation.

Abzu's siRNA design platform enables fast in silico design of new, safer RNA therapeutics. The design platform leverages Abzu's QLattice for modelling drug properties and rigorously screening for potential off-target effects to ensure lead candidates are both active and safe, as well as cross-reactive in the desired species. Together, the partners will launch two co-owned programs, one in dermatology and one in muscle biology, marking Abzu’s transition from service provider to biotech, while ADViRNA continues to support clients as a CRO in parallel.

Martin Kerr, PhD, Head of Business Development & Pharma Partnerships, Abzu, explained: “ADViRNA has been a trusted partner for Abzu, bringing deep expertise and wet-lab strength. Together, we’re moving beyond our roles as CROs to co-develop innovative siRNA assets, starting with programs in dermatology and muscle biology. This marks a major step in Abzu’s transition from service provider to biotech.”